Biosimilars are a
The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines. Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market.
Join Us October 21–23 for GRx+Biosims 2024
GRx+Biosims™ 2024 is the leading scientific, regulatory and policy event for the U.S. generics and biosimilars industry! Register now to advance your professional development and gain great understanding of policy that impacts our industry—all while learning directly from FDA experts.
U.S. Generic and Biosimilar Medicines Savings Report
Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are essential to the U.S. healthcare system. The 2023 U.S. Generic & Biosimilar Medicines Savings Report shows savings will continue to grow—with $408 billion saved in 2022, alone.
Recent News
Biosimilars by the Numbers
Approved Biosimilars in the U.S.
$180B
Potential Savings for Patients and Payers
694M
Days of Patient Therapy with Biosimilars
Incremental Days of Biosimilar Therapy
